Comparing Advanced Technologies to Standard Testing for the Diagnosis of Airway Disease in Hospital and Community Settings (BREATHE)
BREATHE: Benchmarking Respiratory Evaluation of Advanced Technologies for Healthcare Excellence
Airway disease, such as chronic obstructive pulmonary disease (COPD), is usually diagnosed through breathing tests like spirometry. However, it requires people to blow forcefully into a machine several times which can be uncomfortable and difficult for some patients.
This study is looking at whether newer technologies and other breathing tests can help diagnose COPD as accurately as standard testing. We will compare these tests in both hospital and community settings. We are interested in understanding how practical and cost-effective these tests are, including how easy they are to use and how comfortable they are for patients to perform.
研究概览
地位
详细说明
Long-term lung conditions such as COPD affect around one in five people and are the third leading cause of death in England. These conditions are often not picked up until they have reached an advanced stage, and sometimes people are given an incorrect diagnosis. They cause breathing difficulties due to lung damage, which cannot be reversed in the case of COPD.
At present, lung conditions are usually diagnosed through breathing tests like spirometry. These tests require people to blow forcefully into a machine several times, which can be uncomfortable and difficult for some patients. They also rely on specialist equipment and must be carried out and interpreted by highly trained professionals. Because there aren't enough of these professionals, waiting lists can be long. Even when spirometry is possible, it does not always detect lung disease early.
Two national NHS programmes - the Community Diagnostic Centre (CDC) programme and the Lung Cancer Screening (LCS) programme - create opportunities to find lung disease earlier. However, the same challenges with spirometry remain.
Recently, new types of lung tests have been developed. These tests may be simpler, quicker, and cheaper to use, but they are not yet part of standard NHS care. We need to find out whether these new tests can identify lung disease as well as, or better than, spirometry, especially at earlier stages. If they can, they may help prevent further lung damage and improve health outcomes. It is also important to understand how practical and cost-effective these tests are, and whether they could be used widely in different healthcare settings.
To explore this, we will carry out the new tests alongside traditional lung function tests in both community and hospital settings. We will invite adults with possible COPD who:
- have been referred for spirometry at local CDCs,
- have been referred for lung function testing at secondary care hospitals,
- are attending for a lung scan as part of the LCS pathway, and
- are attending local community groups or events.
Participants may also be asked to complete short surveys or optional interviews to share their experiences. Healthcare professionals working in testing centres will be invited to do the same. We are especially keen to hear from people who live with lung conditions or who experience health inequalities, so that we can understand how easy the tests are to use, how comfortable they are, and whether they could work well across different healthcare settings.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Professor Tom M Wilkinson, MBBS PhD FRCP FERS
- 电话号码:02381205341
- 邮箱:t.wilkinson@soton.ac.uk
研究联系人备份
- 姓名:Madison E Geeves, MSc BSc
- 邮箱:m.e.geeves@soton.ac.uk
学习地点
-
-
Hampshire
-
Andover、Hampshire、英国、SP10 3LB
- Hampshire Hospitals NHS Foundation Trust
-
首席研究员:
- Harry S Griffin, PhD HCPC
-
Southampton、Hampshire、英国、SO16 6YD
- University Hospital Southampton NHS Foundation Trust
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- ≥ 18 years of age
- New referral to community or secondary healthcare services
- Clinical suspicion of airway disease/COPD
- Able to provide fully informed written consent
- Able to fully understand and cooperate with the study protocol
- Clinically stable with no contraindications to lung function testing (outlined below)
Exclusion Criteria:
- Confirmed diagnosis of COPD
- Not willing and/or able to provide fully informed written consent to participate
- Has a relative contraindication to lung function testing [18]:
- Recent thoracic, abdominal or eye (e.g. cataract) surgery < 6 weeks
- Unstable cardiovascular status, including recent myocardial infarction or pulmonary embolus < 6 weeks
- Pneumothorax < 6 weeks
- Haemoptysis of unknown origin < 6 weeks
- Thoracic, abdominal or cerebral aneurysm
- Chest infection < 6 weeks
- An acute illness or symptom that might interfere with test performance (e.g. nausea, vomiting).
- The presence of any other clinical condition that would prevent the individual from safely performing lung function tests
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
GP direct access spirometry within community diagnostic centres
Adults with suspected COPD/airway disease referred for spirometry testing at local community diagnostic centres
|
Capnography used in combination with machine learning-derived algorithms, with or without reversibility testing (if indicated on spirometry)
Oscillometry (where applicable), with or without reversibility testing (if indicated on spirometry).
Measures respiratory impedance during normal tidal breathing.
Fractional exhaled nitric oxide (if requested).
Used to assess airway inflammation.
Spirometry, with or without reversibility testing
|
|
Full lung function testing within secondary care hospitals
Adults with suspected COPD/airway disease referred for full lung function testing at secondary care hospitals
|
Capnography used in combination with machine learning-derived algorithms, with or without reversibility testing (if indicated on spirometry)
Oscillometry (where applicable), with or without reversibility testing (if indicated on spirometry).
Measures respiratory impedance during normal tidal breathing.
Fractional exhaled nitric oxide (if requested).
Used to assess airway inflammation.
Spirometry, with or without reversibility testing
Assesses lung diffusing capacity, performed using full pulmonary function testing equipment
Body plethysmography (if applicable).
Used to assess static lung volumes and, where applicable, specific resistance, performed using full lung function equipment
|
|
Low dose-CT scan within lung cancer screening programme
Adults with suspected COPD/airway disease attending for a low-dose CT scan as part of the lung cancer screening programme
|
Capnography used in combination with machine learning-derived algorithms, with or without reversibility testing (if indicated on spirometry)
Oscillometry (where applicable), with or without reversibility testing (if indicated on spirometry).
Measures respiratory impedance during normal tidal breathing.
|
|
Community outreach
Adults with suspected COPD/airway disease attending local community groups and events
|
Capnography used in combination with machine learning-derived algorithms, with or without reversibility testing (if indicated on spirometry)
Oscillometry (where applicable), with or without reversibility testing (if indicated on spirometry).
Measures respiratory impedance during normal tidal breathing.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Diagnostic accuracy of capnography used in combination with machine learning-derived algorithms
大体时间:Baseline
|
Sensitivity, Specificity, PPV, NPV compared to clinician diagnosis of COPD
|
Baseline
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Diagnostic accuracy of oscillometry
大体时间:Baseline
|
Sensitivity, Specificity, PPV, NPV compared to clinician diagnosis of COPD
|
Baseline
|
|
Effectiveness of advanced technologies in detecting early, alternative, or precursor respiratory conditions
大体时间:Baseline
|
Identification of pre-COPD using advanced respiratory diagnostic technologies in patients with normal forced expiratory volume in 1 second (FEV1) / forced vital capacity (FVC) ratio on spirometry but signs of reduced FEV1, gas trapping, hyperinflation, or reduced diffusing capacity on additional lung function tests performed in secondary care, or emphysema on CT scan.
Differentiation of COPD from asthma using advanced diagnostic tests, particularly in patients presenting with overlapping respiratory symptoms
|
Baseline
|
|
Feasibility outcomes in Lung Cancer Screening pathway
大体时间:Baseline
|
Recruitment uptake rate, time required and the acceptability to both patients and healthcare professional to complete additional diagnostic testing in individuals invited for low-dose CT (LDCT) as part of the lung cancer screening (LCS) pathway
|
Baseline
|
|
Time per test
大体时间:Baseline
|
Time per test of advanced diagnostic technologies compared to usual care
|
Baseline
|
|
Comparative 'failure rate'
大体时间:Baseline
|
Comparative 'failure rate' of advanced diagnostic technologies compared to usual care
|
Baseline
|
|
Usability and acceptability
大体时间:Baseline
|
Patients' perceptions on the usability and acceptability of advanced respiratory diagnostic technologies compared to existing tests such as spirometry via a non-validated questionnaire
|
Baseline
|
|
Usability and acceptability
大体时间:Baseline
|
Healthcare practitioners' perceptions on the usability, acceptability and confidence in advanced respiratory diagnostic technologies via semi-structured interviews
|
Baseline
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- DEV DVB0067
- 359125 (其他标识符:IRAS Number)
- RHM RSP0030 (其他标识符:Local Reference Number)
- 25/NE/0225 (其他标识符:REC ID)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.